Wall Street Zen Upgrades Smith & Nephew SNATS (NYSE:SNN) to Strong-Buy

Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Sunday.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a “hold” rating in a research report on Thursday, March 5th. Finally, Royal Bank Of Canada lowered Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Stock Down 0.1%

Shares of Smith & Nephew SNATS stock opened at $31.62 on Friday. The company has a 50-day simple moving average of $34.27 and a two-hundred day simple moving average of $34.34. Smith & Nephew SNATS has a one year low of $23.91 and a one year high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The firm had revenue of $1.60 billion during the quarter. On average, equities research analysts forecast that Smith & Nephew SNATS will post 1.69 earnings per share for the current fiscal year.

Institutional Trading of Smith & Nephew SNATS

Several large investors have recently bought and sold shares of SNN. River Road Asset Management LLC increased its stake in Smith & Nephew SNATS by 9.3% during the 2nd quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock valued at $97,175,000 after purchasing an additional 270,480 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Smith & Nephew SNATS by 5.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after buying an additional 100,697 shares during the period. Brandes Investment Partners LP grew its holdings in shares of Smith & Nephew SNATS by 4.1% during the second quarter. Brandes Investment Partners LP now owns 1,604,400 shares of the medical equipment provider’s stock valued at $49,143,000 after buying an additional 63,778 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Smith & Nephew SNATS by 6,663.4% during the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock valued at $37,082,000 after buying an additional 1,192,755 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Smith & Nephew SNATS by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock valued at $35,828,000 after acquiring an additional 575,666 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.